Dianthus Therapeutics, Inc.
DNTH
Hisse Senetlerindeki Sıralama
#3781
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Hisse Fiyatı
$78.21
Piyasa Değeri
$4.37B
Değişim (1 gün)
-0.69%
Değişim (1 yıl)
123.27%
Ülke
US
Ticaret Dianthus Therapeutics, Inc. (DNTH)
Kategori
Healthcare
Dianthus Therapeutics, Inc. (DNTH) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $80.78 - 2026-10-01
Gün sonu en düşük fiyat: $225.69 - 2018-06-01
Gün sonu en düşük fiyat: $225.69 - 2018-06-01
Dianthus Therapeutics, Inc. için hisse fiyatı geçmişi: 2018 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | 74.03% |
| 2025 | 79.27% |
| 2024 | 158.65% |
| 2023 | -30.65% |
| 2022 | -83.63% |
| 2021 | -32.46% |
| 2020 | -46.40% |
| 2019 | 100.40% |
| 2018 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $518.20 | 21.57% |
US
|
|
| $243.77 | 786.76% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $879.20 | 5.32% |
NL
|
|
| $752.87 | 7.40% |
CH
|
